Cargando…

Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma

SIMPLE SUMMARY: The escalating use of Next Generation Sequencing in the routine clinical setting greatly facilitates the genetic diagnosis of hereditary cancer syndromes. However, these novel methods pose new and unique challenges. In our study we sought to demonstrate the evolution of these techniq...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarkadi, Balazs, Liko, Istvan, Nyiro, Gabor, Igaz, Peter, Butz, Henriett, Patocs, Attila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392134/
https://www.ncbi.nlm.nih.gov/pubmed/34439371
http://dx.doi.org/10.3390/cancers13164219
_version_ 1783743430687457280
author Sarkadi, Balazs
Liko, Istvan
Nyiro, Gabor
Igaz, Peter
Butz, Henriett
Patocs, Attila
author_facet Sarkadi, Balazs
Liko, Istvan
Nyiro, Gabor
Igaz, Peter
Butz, Henriett
Patocs, Attila
author_sort Sarkadi, Balazs
collection PubMed
description SIMPLE SUMMARY: The escalating use of Next Generation Sequencing in the routine clinical setting greatly facilitates the genetic diagnosis of hereditary cancer syndromes. However, these novel methods pose new and unique challenges. In our study we sought to demonstrate the evolution of these techniques, especially whole exome sequencing and targeted panel sequencing. This study highlights the multi-layered workflow and how each step affects the diagnostic outcome and demonstrates the effectiveness of an in-house developed targeted panel sequencing for hereditary endocrine tumor syndromes. ABSTRACT: Next Generation Sequencing (NGS)-based methods are high-throughput and cost-effective molecular genetic diagnostic tools. Targeted gene panel and whole exome sequencing (WES) are applied in clinical practice for assessing mutations of pheochromocytoma/paraganglioma (PPGL) associated genes, but the best strategy is debated. Germline mutations of at the least 18 PPGL genes are present in approximately 20–40% of patients, thus molecular genetic testing is recommended in all cases. We aimed to evaluate the analytical and clinical performances of NGS methods for mutation detection of PPGL-associated genes. WES (three different library preparation and bioinformatics workflows) and an in-house, hybridization based gene panel (endocrine-onco-gene-panel- ENDOGENE) was evaluated on 37 (20 WES and 17 ENDOGENE) samples with known variants. After optimization of the bioinformatic workflow, 61 additional samples were tested prospectively. All clinically relevant variants were validated with Sanger sequencing. Target capture of PPGL genes differed markedly between WES platforms and genes tested. All known variants were correctly identified by all methods, but methods of library preparations, sequencing platforms and bioinformatical settings significantly affected the diagnostic accuracy. The ENDOGENE panel identified several pathogenic mutations and unusual genotype–phenotype associations suggesting that the whole panel should be used for identification of genetic susceptibility of PPGL.
format Online
Article
Text
id pubmed-8392134
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83921342021-08-28 Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma Sarkadi, Balazs Liko, Istvan Nyiro, Gabor Igaz, Peter Butz, Henriett Patocs, Attila Cancers (Basel) Article SIMPLE SUMMARY: The escalating use of Next Generation Sequencing in the routine clinical setting greatly facilitates the genetic diagnosis of hereditary cancer syndromes. However, these novel methods pose new and unique challenges. In our study we sought to demonstrate the evolution of these techniques, especially whole exome sequencing and targeted panel sequencing. This study highlights the multi-layered workflow and how each step affects the diagnostic outcome and demonstrates the effectiveness of an in-house developed targeted panel sequencing for hereditary endocrine tumor syndromes. ABSTRACT: Next Generation Sequencing (NGS)-based methods are high-throughput and cost-effective molecular genetic diagnostic tools. Targeted gene panel and whole exome sequencing (WES) are applied in clinical practice for assessing mutations of pheochromocytoma/paraganglioma (PPGL) associated genes, but the best strategy is debated. Germline mutations of at the least 18 PPGL genes are present in approximately 20–40% of patients, thus molecular genetic testing is recommended in all cases. We aimed to evaluate the analytical and clinical performances of NGS methods for mutation detection of PPGL-associated genes. WES (three different library preparation and bioinformatics workflows) and an in-house, hybridization based gene panel (endocrine-onco-gene-panel- ENDOGENE) was evaluated on 37 (20 WES and 17 ENDOGENE) samples with known variants. After optimization of the bioinformatic workflow, 61 additional samples were tested prospectively. All clinically relevant variants were validated with Sanger sequencing. Target capture of PPGL genes differed markedly between WES platforms and genes tested. All known variants were correctly identified by all methods, but methods of library preparations, sequencing platforms and bioinformatical settings significantly affected the diagnostic accuracy. The ENDOGENE panel identified several pathogenic mutations and unusual genotype–phenotype associations suggesting that the whole panel should be used for identification of genetic susceptibility of PPGL. MDPI 2021-08-22 /pmc/articles/PMC8392134/ /pubmed/34439371 http://dx.doi.org/10.3390/cancers13164219 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sarkadi, Balazs
Liko, Istvan
Nyiro, Gabor
Igaz, Peter
Butz, Henriett
Patocs, Attila
Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma
title Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma
title_full Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma
title_fullStr Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma
title_full_unstemmed Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma
title_short Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma
title_sort analytical performance of ngs-based molecular genetic tests used in the diagnostic workflow of pheochromocytoma/paraganglioma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392134/
https://www.ncbi.nlm.nih.gov/pubmed/34439371
http://dx.doi.org/10.3390/cancers13164219
work_keys_str_mv AT sarkadibalazs analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma
AT likoistvan analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma
AT nyirogabor analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma
AT igazpeter analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma
AT butzhenriett analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma
AT patocsattila analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma